Initiation of patient recruitment marks a key milestone in the development of VAR 200, a potential first-in-class treatment for kidney disease addressing renal lipotoxicity.There are no available drugs targeting renal lipotoxicity that damages the kidneys’ filtration system, causing protein leakage into the urine (proteinuria) and disease progression.VAR 200, designed to alleviate renal lipid accumulation, has preclinical data in three types of kidney disease (DKD, Focal Segmental Glomerulosclerosis, Alport ...